Your browser doesn't support javascript.
loading
Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors.
Abu-Arja, Mohammad H; Osorio, Diana S; Lassaletta, Alvaro; Graham, Richard T; Coven, Scott L; Stanek, Joseph R; Bouffet, Eric; Finlay, Jonathan L; Abdelbaki, Mohamed S.
Afiliação
  • Abu-Arja MH; Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
  • Osorio DS; The Division of Hematology, Oncology and BMT, The Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
  • Lassaletta A; The Division of Hematology, Oncology and BMT, The Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
  • Graham RT; The Department of Pediatric Oncology, Hospital Universitario Niño Jesús, Madrid, Spain.
  • Coven SL; The Division of Hematology, Oncology and BMT, The Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
  • Stanek JR; The Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Bouffet E; The Division of Hematology, Oncology and BMT, The Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
  • Finlay JL; The Division of Pediatric Hematology-Oncology, Riley Hospital for Children and Indiana University School of Medicine, Indianapolis, Indiana.
  • Abdelbaki MS; The Division of Hematology, Oncology and BMT, The Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
Pediatr Blood Cancer ; 69(1): e29365, 2022 01.
Article em En | MEDLINE | ID: mdl-34558189
We aimed toidentify prognostic factors that may help better understand the behavior of relapsed central nervous system nongerminomatous germ cell tumors. We identified nine studies, including 101 patients; 33 patients (33%) were alive 12 months post-initial relapse. Sixty percent of patients with serum/cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) level ≤25 ng/mL at initial diagnosis were survivors compared with 28% among patients with serum/CSF AFP level >25 ng/mL (P = 0.01). Seventy-one percent of patients who achieved complete response/continued complete response (CR/CCR) by the end of therapy at relapse were survivors compared with 7% among patients who had less than CR/CCR (P < 0.0001). Forty-eight percent of patients who received marrow-ablative chemotherapy followed by autologous hematopoietic cell rescue (HDCx/AuHCR) following relapse were survivors compared with 12% among patients who did not receive HDCx/AuHCR (P = 0.0001). Local relapse site, gross total surgical resection, and radiotherapy at relapse were not associated with improved outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias do Sistema Nervoso Central / Neoplasias Embrionárias de Células Germinativas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias do Sistema Nervoso Central / Neoplasias Embrionárias de Células Germinativas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2022 Tipo de documento: Article